ClinicalTrials.Veeva

Menu
D

Desert Hematology Oncology Medical Group, Inc. | Rancho Mirage, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Gemcitabine
Carboplatin
Docetaxel
Paclitaxel
Avelumab
Azacitidine
Cemiplimab
Pembrolizumab
Lenalidomide
Prednisone

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 41 total trials

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

To evaluate whether Fuzuloparib plus AA-P is superior to placebo plus AA-P as first-line treatment by assessment of radiographic progression-free sur...

Enrolling
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Drug: Fuzuloparib Placebo, Abiraterone acetate and Prednisone
Drug: Fuzuloparib , Abiraterone acetate and Prednisone

This is a Phase I/II, multicenter, open-label study to evaluate the safety, efficacy, tolerability, and pharmacokinetics of a novel BTK inhibitor, Or...

Active, not recruiting
Part 2:B-cell Malignancies
Part 1:r/r B-cell Malignancies
Drug: Orelabrutinib (ICP-022)

This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab (also called REG...

Enrolling
Advanced Non-Small Cell Lung Cancer
Drug: cemiplimab
Drug: Placebo

This study is researching an investigational drug called fianlimab (also called REGN3767) with two other medications called cemiplimab and chemothera...

Enrolling
Non-small Cell Lung Cancer
Drug: Pemetrexed
Drug: fianlimab

This is a phase 3, open-label, 4-cohort study (3 randomized cohorts and 1 single-arm cohort). Participants enrolled in each cohort will be treated as...

Active, not recruiting
Non Small Cell Lung Cancer
Drug: N-803 + Carboplatin + Nab-paclitaxel + Pembrolizumab
Drug: Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed

This is a Phase IIb, multicohort, open-label multicenter study of combination immunotherapies in patients who have previously received treatment with...

Active, not recruiting
Microsatellite Instability
Melanoma
Drug: N-803 + Atezolizumab + PD-L1 t-haNK
Drug: N-803 + Pembrolizumab

Trial sponsors

Celgene logo
Celgene logo
ImmunityBio logo
Nektar Therapeutics logo
Regeneron Pharmaceuticals logo
T
AVEO Pharmaceuticals logo
Achieve Life Sciences logo
Astex Pharmaceuticals logo
A

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems